Birth control, population aging, and medicine have made life expectancy longer. However, this has facilitated an increase in the presence of neurodegenerative diseasesNeurodegenerative disease, which are proteinopathies that cause a functional deterioration of those who suffer them, mainly affecting cognition and motor skills, manifesting as dementia, parkinsonian syndromes, motor neuron disease, behavioral and movement disorders. The in-life diagnosisDiagnosis of these processes remains a real challenge, so the search for biomarkersBiomarkers that allow us to approach the risk of suffering from these processes becomes mandatory. The skin, having a neuroectodermal origin, must share a protein synthesis program like that of nervous tissue, so it could be an ideal site to find the characteristic alterations of synucleinopathiesSynucleinopathies (Parkinson’s diseaseParkinson´s disease) and tauopathiesTauopathies (Alzheimer’s diseaseAlzheimer´s disease), the two epidemiologically most important proteinopathies by incidence and prevalence in the world. Modification of proteins that were functionally and structurally useful to cells will eventually lead to the formation of aggregates that in neurons are recognized as the main characteristic for these pathologies: Lewy bodies (with α-synuclein for Parkinson’s disease) and neurofibrillary tangles (with Tau for Alzheimer’s disease). We have demonstrated different patterns of distribution of these proteins in the skinSkin of affected subjects, and in this chapter, we tell the story that summarizes ten years of teamwork to achieve a goal, to demonstrate that the skin can be a site of neurodegenerationNeurodegeneration labeling.